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Microglial-associated responses to
comorbid amyloid pathology and
hyperhomocysteinemia in an aged knock-in
mouse model of Alzheimer’s disease
David J. Braun1*, Edgardo Dimayuga1, Josh M. Morganti1,2,3 and Linda J. Van Eldik1,2,3*
Abstract
Background: Elevated blood homocysteine levels, termed hyperhomocysteinemia (HHcy), is a prevalent risk factor
for Alzheimer’s disease (AD) in elderly populations. While dietary supplementation of B-vitamins is a generally
effective method to lower homocysteine levels, there is little if any benefit to cognition. In the context of amyloid
pathology, dietary-induced HHcy is known to enhance amyloid deposition and certain inflammatory responses.
Little is known, however, about whether there is a more specific effect on microglia resulting from combined
amyloid and HHcy pathologies.
Methods: The present study used a knock-in mouse model of amyloidosis, aged to 12 months, given 8 weeks of B-
vitamin deficiency-induced HHcy to better understand how microglia are affected in this comorbidity context.
Results: We found that HHcy-inducing diet increased amyloid plaque burden, altered the neuroinflammatory
milieu, and upregulated the expression of multiple damage-associated and “homeostatic” microglial genes.
Conclusions: Taken together, these data indicate complex effects of comorbid pathologies on microglial function
that are not driven solely by increased amyloid burden. Given the highly dynamic nature of microglia, their central
role in AD pathology, and the frequent occurrence of various comorbidities in AD patients, it is increasingly
important to understand how microglia respond to mixed pathological processes.
Keywords: Alzheimer’s disease, Amyloid, Homocysteine, Hyperhomocysteinemia, Microglia, Neuroinflammation
Background
Homocysteine (Hcy) is an intermediary in essential cel-
lular pathways, and its metabolism depends on several
vitamin cofactors, primarily B6, B9 (folic acid), and B12.
Deficiencies in one or more of these are therefore a
common cause of elevated blood homocysteine, termed
hyperhomocysteinemia (HHcy) [1]. Evidence indicates
that both elevated homocysteine itself, and the broader
metabolic dysfunctions resulting from B-vitamin defi-
ciency, are relevant to its status as a vascular risk factor
and risk factor for Alzheimer’s disease (AD) [2–4]. The
normal human range for Hcy in plasma is generally con-
sidered to be less than 15 μM, with increasing levels cat-
egorized as moderate (15–30 μM), intermediate (30–
100 μM), or severe (> 100 μM) HHcy. Although the
prevalence of HHcy in the general population is esti-
mated to be around 5%, it is significantly higher in the
elderly [5], a population in which B-vitamin status is a
major contributor to HHcy [6]. Interestingly, elderly
men have been found to have elevated plasma
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: david.braun1@uky.edu; linda.vaneldik@uky.edu
1Sanders-Brown Center on Aging, University of Kentucky, 101 Sanders-Brown
Bldg., 800 S. Limestone Street, Lexington, KY 40536, USA
Full list of author information is available at the end of the article
Braun et al. Journal of Neuroinflammation          (2020) 17:274 
https://doi.org/10.1186/s12974-020-01938-7
homocysteine compared to women [7], while AD is
more common in women [8], highlighting that HHcy is
only one in a complex array of factors influencing any
given individual’s risk of dementia. Nonetheless, the
population attributable risk of dementia from raised Hcy
is estimated to be between 4 and 31%; in other words,
preventing HHcy could prevent somewhere between 1
in 25 to 1 in 3 cases of AD [9]. In the USA alone, even
the conservative estimate would translate to hundreds of
thousands of people. It follows, then, that reduction of
HHcy in the population is an attractive goal. In addition
to lifestyle modifications (e.g., quitting smoking, exer-
cise), B-vitamin supplementation is a fairly straightfor-
ward intervention that reduces circulating Hcy levels
and thus the prevalence of HHcy [10]. Encouragingly,
since the USS began supplementing grain with folic acid
in the late 1990’s, the prevalence of HHcy has roughly
halved [11], and this could potentially be a contributor
to the recently reported reductions in the rate of in-
crease in AD incidence [12]. Nonetheless, correcting the
acute metabolic dysfunctions underlying elevated Hcy
appears to be a necessary but insufficient step to abro-
gate the full contribution of this risk factor to AD-
associated cognitive decline [9], and adjunct treatments
will likely be important moving forward.
HHcy-related neural dysfunction is a multifactorial
pathological process, mediated by complex and interact-
ing pathways related to oxidative damage, inflammation,
hypomethylation, and others [13]. In this regard, it
shares commonalities with AD, and there may be im-
portant points of convergence amenable to therapeutic
targeting. Recent work has highlighted the role of micro-
glia as a nexus in the development and progression of
AD pathology (for review see [14]), with particular focus
on a shift of microglia from a more “homeostatic”
phenotype to a damage-associated or neurodegenerative
(DAM) phenotype [15, 16]. The microglial responses to
pathological Hcy elevation are less well-characterized,
but there is evidence that homocysteine directly in-
creases activation of microglial-type cells in vitro [17,
18], and both direct Hcy supplementation [19] and vita-
min deficiency-induced HHcy have similar impacts
in vivo [20–22]. Microglial dysregulation could therefore
represent an important convergence point in the context
of comorbid HHcy and amyloid pathology. There are
several major possibilities here that are relevant from a
treatment standpoint and not mutually exclusive: the co-
morbidity context accentuates dysfunctional microglial
responses to amyloid, it induces more of the microglia
to assume a dysfunctional DAM state, or it causes some
emergent alteration unique to these comorbid patholo-
gies. The goal of the present study is to better under-
stand these possibilities by using a knock-in (KI) mouse
model of amyloidosis with mutant presenilin 1 and
amyloid precursor protein transgenes under control of
endogenous promoters to avoid potential overexpression
artifacts [23]. Male and female mice aged 12months
were placed on B-vitamin deficient diet for 8 weeks, with
the effect on various neuroinflammatory and microglial
parameters characterized at the conclusion of dietary ad-
ministration, when mice were about 14 months old. We
found that elevation of homocysteine level in the context
of amyloid pathology enhances parenchymal plaque de-
position, subtly alters the neuroinflammatory milieu, and
influences a number of genes important to microglial
functioning. Interestingly, these changes are consistent
with both an increase in DAM microglia as well as some
emergent effects on microglia-relevant pathways. This
study lays the groundwork for follow-up experiments
making use of cell-specific isolation and next generation
sequencing technologies.
Methods
Animals and experimental design
All mice were housed 1–5 per cage (503.22 usable cm2)
in a room at 23 °C ± 2 °C, under a 14/10-h light/dark
cycle beginning at 6:00 AM, with ad libitum access to
water and chow. The APPNLh/NLh × PS1P264L/P264L
double knock-in (KI) mouse model expresses humanized
amyloid precursor protein with the Swedish mutation
(K670N/M671L), along with a P264L point mutation in
the mouse presenilin 1 gene [24]. The homozygous KI
mice were maintained on a combined CD-1/129 back-
ground, with wildtype (WT) controls derived separately
from matings of heterozygous KI animals. The experi-
ment was carried out in a 2 × 2 diet by genotype design,
where half the mice of each genotype were randomized
to receive 8 weeks of control (Envigo, #TD.01636) or
HHcy diet (Envigo, #TD.97345), beginning between 52
and 54 weeks of age (M = 53.4 weeks, SD = 0.36). The
HHcy diet was deficient in vitamins B6, B9, and B12 and
supplemented with excess methionine, while the control
diet was nutritionally matched with normal methionine
and B-vitamin levels [25]. Humane-endpoint criteria
were 20% weight loss across the study or 10% weight
loss within two weeks, along with detrimental changes
in body condition (e.g., lethargy, hunched posture, dehy-
dration, dermatitis). None of the mice reached humane-
endpoint criteria; however, three mice died during the
study and were excluded from all analyses: one KI fe-
male receiving HHcy diet, one WT male receiving con-
trol diet, and one WT male receiving HHcy diet.
Importantly, mice were randomized irrespective of sex,
resulting in an imbalance in the final sex ratios. The final
numbers of mice for each group were 8 WT on control
diet (5 female and 3 male), 10 WT on HHcy diet (5 fe-
male and 5 male), 11 KI on control diet (4 female and 7
male), and 10 KI on HHcy diet (8 female and 2 male).
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As the experiment was not powered to detect sex differ-
ences, it should be noted that the imbalance may have
increased experimental variability and thus reduced stat-
istical power, or otherwise influenced the data. The ex-
periment was performed in compliance with the
Institutional Animal Care and Use Committee of the
University of Kentucky.
Tissue collection and blood analyses
Mice were deeply anesthetized with 5% isoflurane, and
arterial blood collected from the left ventricle and placed
into EDTA-plasma tubes (Greiner Bio-One, #454428)
for separation of plasma by centrifugation (2000×g for
20 min at room temperature) followed by storage at −
80 °C. As an interim analysis to verify the expected diet-
ary effects, a subset of 7 WT mice (4 on HHcy and 3 on
control diet) had whole blood taken for hematologic
analysis using i-STAT CG8+ cartridges (Abbott Labora-
tories) according to the manufacturer’s instructions.
Additionally, at the conclusion of the full study, plasma
samples from a randomly chosen subset of 5 mice per
group (20 total) were diluted 1:5 in ARCHITECT Multi-
Assay Manual Diluent (Abbott Laboratories, Chicago, IL,
USA) and delivered to the University of Kentucky Clin-
ical Laboratory for Hcy measurement on an ARCHITEC
T i2000SR analyzer (Abbott Laboratories). Samples were
diluted to reach the volume requirements for the assay
(500 μL). The lower limit of detection is 1 μM, and di-
luted samples reading less than 1 do not give an output
value. Samples with an output value > 1 μM were multi-
plied by the dilution factor to determine the total homo-
cysteine concentration in the undiluted plasma. None of
the diluted samples from mice on control diet gave a
reading of greater than 1 μM.
All mice subsequently underwent transcardial perfu-
sion with 50 ml ice-cold phosphate-buffered saline (PBS)
at a flow rate of 10 ml/min before decapitation and brain
removal and dissection. The right hemisphere was post-
fixed in 4% paraformaldehyde for 24 h at 4 °C and cryo-
protected in 30% sucrose for at least 48 h at 4 °C. Sam-
ples were subsequently cut into 30 μm sections with a
sliding microtome and stored in cryoprotectant solution
at − 20 °C prior to immunofluorescent staining. The
hippocampus and overlying cortex were dissected from
the left hemisphere, flash frozen in liquid nitrogen, and
stored at − 80 °C until processing for biochemical end-
points described below. The cortex was divided in two: a
more caudal piece directly overlying the hippocampus
was used for protein analysis. An adjacent rostral piece
was used for mRNA expression analysis. A portion of
dorsal hippocampus was used for protein analysis. See
supplement 1 for an illustration of brain regions dis-
sected and outlined for analysis.
Immunofluorescence
Staining was performed on free-floating sections spaced
approximately 300 apart through the dorsal hippocam-
pus and overlying cortex, for a total of 6–8 sections per
animal. Blocking was performed with 10% normal goat
serum (Lampire Biological Laboratories, #7332500) and
0.2% Triton X-100 in PBS. All antibodies were diluted in
PBS with 3% normal goat serum and 0.2% Triton X-100.
Sections were incubated overnight at 4 °C with rabbit
anti-P2ry12 (1:500, Anaspec #AS-55043A) and mouse
anti-Aβ 6E10 conjugated to Alexa 647 (1:200, BioLegend
#803021). Samples were subsequently incubated at room
temperature for 2 h in 1:500 secondary antibody solution
with Alexa 488 goat anti-rabbit (Invitrogen, #A-11034).
Sections were mounted and treated for 5 min with 1x
TrueBlack (VWR, #10119-144) in 70% ethanol to reduce
autofluorescence before drying and coverslipping in Vec-
tashield mounting medium with DAPI (Vector Labora-
tories, #H-1200). Entire slides were imaged on a Zeiss
Axio Scan Z1 digital slide scanner at × 20 magnification.
Image analysis
The dorsal hippocampus and overlying cortex were
manually outlined in the HALO analysis suite (Indica
Labs, version 2.3.2089.34) by an investigator blinded to
experimental groups. The algorithm minimum intensity
settings for all analyses were manually thresholded based
upon negative control (no primary antibody). For cor-
tical and hippocampal analyses of P2ry12 staining, and
P2ry12 and 6E10 co-localization, the positive pixel algo-
rithm (Area Quantification FL v1.2) was applied to the
traced region across all sections per animal to give a sin-
gle value of total percent area stained per region per
mouse. For cortical and hippocampal analyses of 6E10
staining, the object counter algorithm (Object Colocali-
zation FL v1.0) was applied to the traced region across
all sections to give a single average count per square
millimeter of tissue per region. Minimum object size
was set to 10 μm2. Plaque size distributions were ana-
lyzed in two ways. First, plaques were binned into small
(< 300 μm2), medium (301 to 900 μm2) and large (901+
μm2) size ranges. Arbitrary cutoff points were based on
a previous study of this model [26], and the average
number of plaques/mm2 within each bin were deter-
mined per animal and compared between diet groups.
Second, cumulative size distribution curves were gener-
ated for each diet by treating each plaque as an individ-
ual data point within each dietary condition, and testing
the curves for difference with the Kolmogorov-Smirnov
test [27]. For the spatial analysis of microglia around
amyloid plaques, 1–4 individual plaques were manually
circled per section within the outlined cortical region,
totaling 15 plaques per animal or 120 per diet condition.
This number was based upon the plaque sampling rate
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used in the previous reference [24] of about 100 per
condition. The circle annotation tool was used to manu-
ally circle the entirety of the plaque, and 3 outward con-
centric partitions added with a fixed width of 30 μm.
The positive pixel algorithm was applied within each
ring (inner, middle, and outer). To be selected, plaques
had to be far enough away from tissue edges or other
plaques to enable non-overlapping ROIs completely con-
tained within the tissue. The semi-randomly selected
plaques had a significantly larger median size
(215.6 μm2) than the full distribution (51.5 μm2), likely
because the smallest plaques tended to be more clus-
tered and therefore not amenable to this analysis. None-
theless, the median size of the plaques analyzed did not
differ between the control (293.7 μm2) or HHcy
(219.8 μm2) dietary groups (two-tailed Mann-Whitney
U, p = 0.235). The cumulative size distributions of the
circled plaques were also not significantly different be-
tween the two groups (Kolmogorov-Smirnov, D = 0.099,
p = 0.482).
MesoScale Discovery (MSD) multiplex ELISA
Pieces of the dissected hippocampus and cortex from
the left hemisphere were used that approximate the re-
gions outlined for the immunofluorescence analyses in
the right hemisphere. Tissues from each mouse were ho-
mogenized using an Omni Bead Ruptor 24 (Omni Inter-
national) at a 1:20 weight to volume ratio in lysis buffer:
PBS with 1mM PMSF, 0.5 mM EDTA and 0.2X Halt
Protease Inhibitor Cocktail (Thermo Scientific, #87786).
Homogenates were centrifuged at 12,000×g for 20 min at
4 °C. Supernatants were collected for cytokine or Aβ1–40
(Aβ40)/Aβ1–42 (Aβ42) measurement using MSD custom
mouse V-Plex ELISA kits and a human 6E10 Aβ kit
(K15200E), respectively. IL-1β, IL-6, TNFα, and CXCL1
were run multiplexed as part of the Proinflammatory
Panel 1 Mouse Kit (K15048). CCL3 and IL-33 were sep-
arately run multiplexed as part of the Cytokine Panel 1
Mouse Kit (K15245). All samples were run undiluted.
For the cytokines, samples were incubated overnight at
4 °C. Samples were incubated for 2 h at room
temperature for the Aβ kit. Cytokine levels and Aβ pep-
tide levels were normalized to the total milligrams (mg)
of protein loaded in the sample as determined by BCA
Protein Assay (ThermoFisher #23225).
Quantitative reverse-transcriptase polymerase chain
reaction (qRT-PCR)
RNA was isolated from the cortical tissue piece just ros-
tral to that used for protein extraction with the RNeasy
Plus Mini Kit (Qiagen, #74136) according to the manu-
facturer’s instructions. Tissue was weighed and homoge-
nized in an appropriate volume of buffer, and genomic
DNA removed with the gDNA eliminator column. The
samples were mixed with 70% ethanol, run through the
RNeasy column, washed, and eluted in RNase-free water.
Quantity and quality of RNA and 260/280 absorbance
ratios were assessed using a NanoDrop spectrophotom-
eter (ThermoFisher Scientific). Reverse transcription was
performed with the High Capacity cDNA Reverse Tran-
scription kit (Applied Biosystems, #4368814) according
to the manufacturer’s protocol. Real-time PCR was per-
formed on a ViiA 7 Real-Time PCR System (Applied
Biosystems) using individual TaqMan® probes for
P2ry12, Clec7a, and Itgax and custom TaqMan®Array
Cards (ThermoFisher Scientific, #4342253) with Taq-
Man Fast Advanced Master Mix (ThermoFisher Scien-
tific, #4444557). See Table 1 for a complete list of genes
and probes included on the array. Established microglial
markers affected by amyloid pathology were chosen
based on recent studies [15, 16]. Relative gene expres-
sion was calculated using the 2−ΔΔCT method and log2
normalized. HPRT and 18S were used as housekeeping
genes for the individual probes and the custom array,
respectively.
Statistical analysis, figure generation, and reporting
Analyses and figure generation were performed with
JMP Pro 14 (SAS) and Prism 8.3.0 (GraphPad). Two-way
analysis of variance (ANOVA) with Sidak’s or Dunnett’s
post hoc testing, student’s t tests, or non-parametric
Mann-Whitney U tests as indicated in the figure legends
or text. For plaque size analysis, Kolmogorov-Smirnov
tests were used to determine whether the cumulative
plaque size distributions differed between dietary groups.
For the gene expression data, three group comparisons
were made: WT HHcy versus WT control, KI control vs
WT control, and KI HHcy versus KI control. To gener-
ate the heatmap, group scores were averaged and trans-
formed into z-scores using JMP; then, the variable
clustering script was run to group genes by similarity of
expression pattern prior to visualization in Prism. Where
reported in the text, group means are followed by the
standard deviation (SD).
Results
Eight weeks of B-vitamin-deficient and methionine-
supplemented diet induces HHcy and increases plaque
deposition in the KI mice
The average plasma homocysteine levels after HHcy diet
were similar between genotypes, with WT mice achiev-
ing an average concentration of 19.0 μM (SD = 6.8 μM)
versus 14.7 μM (SD = 2.8 μM) in the KI animals (for full
dietary validation data see supplement 2). The plasma
samples from all mice on control diet were below the
limit of detection for the test after dilution—meaning
the undiluted samples were less than 5 μM—consistent
with what has been reported in the literature by
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ourselves and others [25, 28]. Additionally, we found
that in the KI mice HHcy was associated with greater
amyloid plaque burden in the cortex and hippocam-
pus, as measured by 6E10 percent area positivity, and
corresponding with an increase in the total number
of plaques (Fig. 1a–c). In the cortex, average plaque
number increased from 13.3 per mm2 (SD = 6.1) in
KI mice on control diet to 29.4 mm2 (SD = 17.3) in
those on HHcy diet. Hippocampal plaques increased
from 3.9 (SD = 3.3) to 10.1 (SD = 8.7) per mm2 in
mice on control or HHcy diet, respectively. No
changes were detected in hippocampal or cortical
levels of Aβ40, Aβ42, nor the Aβ42/40 ratio as mea-
sured by ELISA (Fig. 1d–i). Notably, no evidence of
cerebral amyloid angiopathy (CAA) was found.
Next, amyloid plaque size analysis was performed in
cortex and hippocampus in two ways. First, plaques were
binned into small (10–300 μm2), medium (301–
900 μm2), and large sizes (901+ μm2), with average pla-
ques/mm2 in each bin compared across dietary condi-
tions (Fig. 2a) [26]. This analysis showed an increase in
smaller plaques in the cortex, consistent with increased
plaque deposition (Fig. 2), as well as an increase in the
medium-sized plaques possibly representing growth of
extant plaques. The increase of plaque number in these
bins did not reach statistical significance in the hippo-
campus. Next, cumulative probability distribution histo-
grams were generated for plaque size in each dietary
condition (Fig. 2b) [27]. In accordance with the binned
data analysis, the distribution was significantly shifted
leftward in the cortex of the HHcy versus the control KI
group, indicative of a larger proportion of smaller pla-
ques (Kolmogorov-Smirnov test, p = .0078). This was
not significant in the hippocampus (Kolmogorov-Smir-
nov test, p = 0.78).
Table 1 Gene names and TaqMan probes analyzed in this
study. Genes in bold were run with individual probes: the rest
were run together on TaqMan custom low-density array cards
Gene TaqMan probe
Apoe Mm01307193_g1
B2m Mm00437762_m1
C1qa Mm00432142_m1
C1qb Mm01179619_m1
C1qc Mm00776126_m1
Ccl2 Mm00441242_m1
Ccrl2 Mm00516914_g1
Cd74 Mm00658576_m1
Chil3 Mm00657889_mH
Csf1 Mm00432686_m1
Csf1r Mm01266652_m1
Cst3 Mm00438347_m1
Cst7 Mm00438351_m1
Ctsz Mm00517697_m1
Ctsb Mm01310506_m1
Ctsd Mm00515586_m1
Ctsl Mm00515597_m1
Ctss Mm01255859_m1
Axl Mm00437221_m1
Cx3cr1 Mm02620111_s1
Cyba Mm00514478_m1
Eef1a1 Mm01973893_g1
Egr1 Mm00656724_m1
P2ry13 Mm01951265_s1
F11r Mm00554113_m1
Fcrls Mm00472833_m1
Ftl1 Mm03030144_g1
Fth1 Mm00850707_g1
Golm1 Mm00550918_m1
Gpr34 Mm02620221_s1
Hexb Mm01282432_m1
Hif1a Mm00468869_m1
Kctd12 Mm00624816_s1
Lag3 Mm00493071_m1
Lyz2 Mm01612741_m1
Mafb Mm00627481_s1
Olfml3 Mm00513567_m1
Pde3b Mm00691635_m1
Plxdc2 Mm00470653_m1
Sall1 Mm00491266_m1
Slc11a1 Mm00443045_m1
Slco2b1 Mm00614448_m1
Table 1 Gene names and TaqMan probes analyzed in this
study. Genes in bold were run with individual probes: the rest
were run together on TaqMan custom low-density array cards
(Continued)
Gene TaqMan probe
Spp1 Mm00436767_m1
Tgfbr1 Mm00436964_m1
Tpt1 Mm03009502_g1
Tyrobp Mm00449152_m1
Mertk Mm00434920_m1
18S Hs99999901_s1
Clec7a Mm01183349_m1
P2ry12 Mm00446026_m1
Itgax Mm00498701_m1
Hprt Mm00446968_m1
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Comorbid amyloid and HHcy pathologies subtly enhance
pro-inflammatory cytokine levels
To assess whether the increased amyloid plaque burden
resulted in an exacerbation of pro-inflammatory re-
sponses, we measured levels of the inflammation-
associated molecules CXCL1, CCL3, IL-33, TNFα, IL-6,
and IL-1β by multiplexed MSD ELISA (Fig. 3). The
overall changes in the cytokines measured were modest
with respect to either strain or diet. There was a signifi-
cant main effect of genotype on CCL3 expression in the
cortex (F(1, 35) = 37, p < .0001) and hippocampus (F(1,
35) = 45.04, p < .0001), with significant differences de-
tected by Sidak’s post hoc tests between KI and WT
groups within both dietary conditions. This was also true
of cortical IL-1β (F(1, 35) = 22.52, p < .0001). In the
hippocampus, there was a significant main effect of
genotype on IL-1β (F(1, 35) = 8.45, p = .0063) and also a
significant main effect of diet (F(1, 35) = 7.26, p =
.0108). Sidak’s post-hoc tests showed significant differ-
ences between the KI HHcy and WT HHcy groups as
well as the KI HHcy and KI control groups (Fig. 3b). No
significant differences were detected in levels of CXCL1,
TNFα, or IL-6 in either region as a function of genotype
or diet, but there was a significant diet by genotype
interaction detected in the hippocampal IL-33 data (F(1,
35) = 5.08, p = .0306). Although the interaction was sig-
nificant, post hoc tests for differences between KI and
WT control or KI HHcy and KI control groups did not
reach statistical significance.
HHcy does not alter P2ry12 staining patterns in response
to amyloid pathology
We quantified cortical and hippocampal P2ry12 staining
as a microglia-specific marker [29] (Fig. 4a) indicative of
overall microgliosis without potential inadvertent meas-
urement of infiltrating myeloid cells. There was a signifi-
cant main effect of genotype on P2ry12 staining in the
cortex (F(1, 29) = 9.973, p = 0.0037), but no differences
found in the hippocampus (Fig. 4b). A modest decrease
in P2ry12 staining was observed in the cortex of KI mice
on HHcy versus control diet; however, the difference be-
tween KI mice on HHcy diet and KI mice on control
diet was not statistically significant (p = 0.08).
Given the established downregulation of P2ry12 in
plaque-associated microglia [15, 30], the subtle decrease
in P2ry12 positivity in the cortex might be attributable
either to a straightforward increase in plaque burden, to
a further downregulation of P2ry12 in plaque-associated
microglia when HHcy is present, or both. To clarify
these possibilities, we performed spatial analyses of
P2ry12 and 6E10 plaque staining. We found that the
percent area double-positive for P2ry12 and Aβ 6E10
staining was unaltered within cortex between KI control
(M = .018%, SD = .015) and KI HHcy mice (M = .018%,
.012) (t(18) = 0.0897, p = 0.9295). This was similarly true
in the hippocampus of the KI control (M = .013%, SD =
.009) and HHcy mice (M = .014%, SD = .011) (t(18) =
0.1474, p = 0.8843). To examine the relationship more
closely, a spatial proximity analysis was performed
around a subset of plaques in the cortex (Fig. 5a). Re-
sults were consistent with a lack of dietary effect on the
spatial distribution of P2ry12 staining in response to
amyloid plaques. This was true when assessed either by
total % positive area of P2ry12 staining (Fig. 5b) or aver-
age pixel intensity (Fig. 5c). The relative dearth of
P2ry12 staining and intensity in the inner ring closest to
the plaque is consistent with previous reports of P2ry12
downregulation near plaques [15, 30]. Taken together,
these data indicate that the small decline in overall cor-
tical P2ry12 staining may be primarily attributable to an
increase in overall plaque number.
HHcy modifies microglia-associated gene expression in
WT and KI mice
To begin exploring possible additive or interactive gene
expression changes that occur in the comorbidity con-
text, we measured whole-tissue cortical changes across a
panel of 50 genes implicated in microglial responses to
amyloid pathology (Table 1). A subset of 8 randomly se-
lected mice per group (32 total samples) were used for
the gene expression analysis, with data normalized to
the expression level of WT mice. Chil3 is excluded from
statistical analysis because two of the samples did not
show any detectable level of this gene (see supplement 3
for full dataset). We first assessed whether our panel,
despite not being run on RNA extracted from purified
microglial populations, could detect any of the expected
increase in DAM markers and decrease in homeostatic
markers in the KI control vs WT control comparison.
We found that 6 genes were detectably altered (Fig. 6a).
In line with expectations, the DAM markers Itgax and
Cst7 were upregulated and the homeostatic markers
Golm1 and Csf1r were downregulated. Interestingly, the
homeostatic markers Fcrls and P2ry12 were found to be
upregulated, which could be indicative of an overall in-
crease in the number of microglia.
When comparing WT HHcy and WT control groups,
we found 4 significantly upregulated DAM markers:
Itgax, Cst7, Clec7a, and Tpt1 (Fig. 6b). To determine
whether there was an overall increase in the DAM signal
or evidence of unique transcriptional changes, we next
compared the KI HHcy and KI control groups. Seven
genes were significant within this comparison, and the
average transcript levels of these genes across all 4
groups are displayed in Fig. 7a. Interestingly, not only
some damage-associated genes (Lag3, Clec7a, Lyz2) but
also putative homeostatic markers (C1qb, C1qc, Sall1,
Csf1r) were upregulated in the comorbid condition
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relative to the KI control group. A summary heatmap of
z-scores with significant comparisons is shown in Fig.
7b. The full gene expression dataset is provided in sup-
plement 3, and graphical representations of the proc-
essed data in supplement 4. These findings indicate that
the comorbid pathologies have complex interactive ef-
fects in addition to straightforwardly additive ones. Rep-
lication and extension of these findings using unbiased
whole-transcriptome analyses in isolated microglial (and
other) cells will be an important next step in this line of
research.
Discussion
We report here several major findings that increase our
understanding of physiological changes occurring in the
relatively common context of comorbid amyloid- and
HHcy-associated pathologies, and also lay the ground-
work for follow-up studies. First, 8 weeks of HHcy-
inducing diet is sufficient to produce a large increase in
parenchymal plaque deposition, particularly smaller pla-
ques, without a concomitant change in levels of soluble
Aβ. This implies that interstitial levels of soluble Aβ are
being kept in equilibrium via increased plaque forma-
tion, consistent with the notion that sequestration into
plaques can be a protective response against the more
toxic soluble Aβ species [31]. Our data align with the hy-
pothesis that HHcy can enhance AD risk by increasing
overall amyloid burden, a finding that has been repli-
cated across models of AD and under different methods
of HHcy-induction [21, 32–34]. Importantly, this ap-
pears reflective of what occurs in patient populations,
where plasma Aβ positively correlates with homocyst-
eine levels and elevated Hcy is also associated with
higher brain Aβ accumulation and CAA pathology [35–
38].
Second, HHcy in this model has a small effect on the
pro-inflammatory milieu, at least in terms of the factors
measured in this study. Partially this may be due to our
focus on a limited subset of cytokines chosen primarily
for reported responsiveness to amyloid pathology.
Within this subset, there was only a modest pro-
inflammatory cytokine response overall with CCL3 and
IL-1β elevations driven by genotype. Only IL-1β was in-
creased due to HHcy diet and even this effect was ob-
served only within the hippocampus. Given the lack of a
similar effect in the cortex, it appears that HHcy does
not alter IL-1β levels primarily via increased amyloid.
That the hippocampus is uniquely susceptible to exacer-
bated inflammatory responses in the comorbid context
is intriguing and may be related to its sensitivity to vas-
cular insults, particularly disruptions to the blood-brain
barrier [39], which is a well-described feature of this par-
ticular model of HHcy [21, 25]. Interestingly, there was
also a significant diet by genotype effect on hippocampal
levels of IL-33, although the post hoc comparisons were
non-significant potentially indicating a lack of adequate
statistical power for this comparison. Biologically rele-
vant changes in this pathway may be worth exploring in
future experiments.
Overall, the cytokine data are consistent with previous
studies that indicate an enhancement of pro-
inflammatory responses in either WT or AD model mice
in response to HHcy [20–22, 32]. Despite this, the mag-
nitude of the effect appears to be much smaller in the
present case, and there are several possibilities for this
apparent discrepancy. Notably, the increase in plasma
Hcy level was comparatively less severe in the present
study. This might indicate that the pro-inflammatory re-
sponse is graded depending upon the severity of induced
HHcy. The implication of this scenario is that patients
with severe HHcy may require treatments suppressing
neuroinflammation; those with moderate HHcy may
benefit more from alternative approaches. Alternatively,
the discrepancy might simply be due to the method of
cytokine measurement employed. Previous studies relied
on transcriptional changes as indicative of cytokine
modulation, but the present study more directly mea-
sured protein levels. Because cytokines are subject to
complex regulation at many levels, large changes in cyto-
kine mRNA transcripts may or may not represent
changes at the functional protein level. For example, in a
previous study that measured cortical IL-1β in this KI
mouse strain, a 7-fold increase in IL-1β mRNA occurred
alongside a much more modest 20% increase in level
of the mature protein [26]. Over-reliance on cytokine
transcript levels without confirmation of protein
changes may therefore overestimate or otherwise mis-
represent the actual pro-inflammatory changes in a
given brain region or pathological context. Such pos-
sibilities warrant more complete characterization of
changes to the neuroinflammatory milieu occurring at
(See figure on previous page.)
Fig. 1 Dietary-induced HHcy is associated with increased cortical and hippocampal plaque burden in KI mice. a Representative images of dorsal
cortex from KI mice on control diet (KI control) or HHcy diet (KI HHcy). Nuclei were stained with DAPI and are shown in blue; amyloid beta
plaques were stained with 6E10 antibody and are shown in white. b Total 6E10 % positive area within cortical and hippocampal ROIs is
quantified, showing a statistically significant increase in cortex and hippocampus. The increase in % area positivity for 6E10 corresponded with an
increase in the number of plaques per square millimeter in the cortex and hippocampus (c). Levels of soluble Aβ40, Aβ42, and the Aβ42/40 ratios
were unchanged in both the hippocampus and cortex (d–i). *p < .05, **p < .01, non-parametric Mann-Whitney U tests
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different levels of Hcy elevation, including the rele-
vant transcriptional or translational regulatory mecha-
nisms across contexts.
Although the neuroinflammatory response was rela-
tively mild in this model, there were several important
findings with regard to microglia. When P2ry12 staining
Fig. 2 Dietary-induced HHcy alters the amyloid plaque size distribution in KI mice. a Plaques within each ROI were binned into three ranges: 10–
300 μm2, 301–900 μm2, and 901 μm2 or greater, and compared across dietary condition. The average number of plaques in the first two ranges
was significantly increased in the cortex of KI mice on HHcy versus control diet. Two-way mixed measures ANOVA with Sidak’s post hoc testing, n
= 11 control and 10 HHcy mice, *p < .05. There was also an increase in small plaques in the hippocampus but the increase did not reach
significance. b Cumulative probability histograms were generated for the complete set of analyzed plaques across animals within each dietary
condition, showing that in the cortex there is a slight leftward shift in the distribution, indicative of an increase in smaller-sized plaques.
Kolmogorov-Smirnov test, n = 1727 control and 3399 HHcy plaques in the cortex, and n = 741 control and 1264 plaques in the hippocampus,
**p < .01
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was taken as a marker of microgliosis, we observed the
expected increase in staining within the cortex of KI ver-
sus WT mice, alongside a parallel increase in P2ry12
mRNA level. Interestingly, there was a moderate de-
crease in P2ry12 staining in the KI mice on HHcy diet
relative to those on control diet. No such effect was ob-
served in the WT animals, indicating that the reduction
of P2ry12 staining in the comorbidity model might be
primarily responding to the increase in plaque burden.
Consistent with this, the expected downregulation of
P2ry12 staining as a function of proximity to plaques
was observed [15, 30] and was unchanged by diet.
To further interrogate the relationship between these
pathologies and microglial phenotype, a subset of
microglia-enriched genes was evaluated. Fifty genes were
selected, chosen based upon recently published datasets
derived from microglia isolated from amyloid-
overexpressing mice [15, 16]. Half of the selected
markers are positively regulated due to amyloid path-
ology and considered to be DAM markers. The other
Fig. 3 Dietary-induced HHcy increases hippocampal IL-1β in KI mice. Levels of cortical (a) and hippocampal (b) IL-1β, IL-6, TNFα, CXCL1, IL-33,
and CCL3 are shown in response to diet and genotype. IL-1β levels in cortex are higher in KI mice compared to WT mice, but there is no
additional effect of HHcy diet in this region. In contrast, IL-1β levels are significantly increased by HHcy diet in the hippocampus of KI mice but
not WT mice. CCL3 was elevated in both cortex and hippocampus of KI versus WT mice, but diet did not alter the effect of genotype on this
chemokine. *p < .05, ***p < .005, ****p < .001 versus corresponding WT dietary group, †p < .05 versus KI control, two-way ANOVA with Sidak’s
post hoc tests, n = 8–11 per group
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half are negatively regulated by amyloid pathology and
considered to be homeostatic markers. We sampled both
under the expectation of detecting an increase in some
of the damage markers and a decrease in some of the
homeostatic markers, which is precisely what we ob-
served in comparisons between the KI control and WT
control mice. The damage-associated genes Itgax and
Cst7 were upregulated, and the homeostatic genes
Golm1 and Csf1r were downregulated. Unexpectedly,
the homeostatic genes P2ry12 and Fcrls were found to
be elevated rather than reduced in the KI mice. This
may be reflective of enhanced microgliosis in response
to amyloid overshadowing more subtle effects occurring
in the relatively small subset of plaque-associated
microglia. That more genes were not detected as being
significantly altered in our panel is likely due to some
combination of a lack of a cell-specific signature, the at-
tenuated amyloidosis that occurs in this model relative
to the overexpression models more frequently utilized
(e.g., 5xFAD mice), heterogeneity resulting from the use
of a different background strain [40], or the unbalanced
inclusion of both sexes and potentially increased bio-
logical variability of the sample. Although sex differences
have not been studied in the KI mice, their existence is
plausible given that sexual dimorphism has been ob-
served in some other strains carrying APPswe/PS1dE9
mutations [41]. Further, we have found some indications
that female mice might be differentially susceptible to
(See figure on previous page.)
Fig. 4 Dietary-induced HHcy is associated with a moderate decrease in cortical P2ry12 staining in KI mice. Representative images of cortex from a
WT mouse on control diet (WT control) and KI mouse on control diet (KI control) are shown in a, with P2ry12 in green and DAPI in blue. A
measurement mask is shown with output of the analysis algorithm shown in yellow. Total % positive area is quantified for the cortex and
hippocampus in b. *p < .05 versus WT control mice, two-way ANOVA with Sidak’s post hoc tests, n = 7–10 per group due to exclusion of slides
with out-of-focus areas within the ROIs
Fig. 5 Spatial analysis of P2ry12 positive microglia near plaques in KI. Representative images of concentric, 30-μm width analysis regions are
shown in a where P2ry12 staining is in red, 6E10 staining is in blue, and output of the analysis algorithm is shown in yellow. Total % positive area
for P2ry12 is quantified in b, and average pixel intensity (AU) within each region shown in c. **p < .01, ***p < .005, ****p < .001 versus the inner
ring within dietary groups. Two-way mixed measures ANOVA with Dunnett’s post hoc tests
Braun et al. Journal of Neuroinflammation          (2020) 17:274 Page 12 of 17
the deleterious effects of this particular HHcy diet [25].
Given the sexual dimorphism that exists clinically in
both AD and HHcy contexts, it will be important to iso-
late sex as a variable in future studies.
In addition to the transcripts responsive to amyloid,
we found 4 responsive to HHcy diet in the WT mice:
Itgax, Cst7, Clec7a, and Tpt1. That Itgax and Cst7 are
upregulated due to HHcy as well as amyloid is consistent
with the frequently described elevation of these genes
across pathological contexts [42]. Clec7a is notable in
that little response of this transcript was detectable in
the KI control mice relative to WT control. Clec7a is a
pathogen-associated molecular pattern receptor involved
in the innate immune response, including microglial
phagocytic responses [43], and it has been shown to in-
crease in parallel with plaque burden in mouse models
of AD [44]. The most parsimonious explanation for
these data is that HHcy increases Clec7a mRNA in a
wider population of microglia throughout the cortex,
whereas plaque deposition is associated with increased
Clec7a mRNA primarily in those microglia that are
closely plaque-associated. When amyloid and HHcy co-
occur, there may be both an increase in Clec7a mRNA
across the wider microglial population, as well as an in-
crease in the proportion of microglia that are plaque-
associated (due to the enhanced amyloid burden). Inter-
estingly, Clec7a has been reported to respond to neur-
onal damage rather than the presence of Aβ per se [15].
The HHcy diet may therefore be causing significant
neuronal damage, and a closer examination of the effect
of the HHcy diet on neuronal health and functioning in
relationship to microglial parameters in both the WT
and KI conditions should be investigated in future work.
Tpt1 is a gene implicated in the cellular DNA damage
response, known to be upregulated in the context of
folic acid deficiency and homocysteine elevation (and
amyloid itself) [45]. That this response was not observed
in the KI mice with HHcy might be due to the pre-
existing pathway activation due to the presence of amyl-
oid. Taken together, these data indicate that the gene ex-
pression panel is successfully detecting expected
pathology-associated changes in gene expression levels
when applied to the whole tissue.
Regarding the primary question of how microglia react
in the comorbidity context, there are several possibilities
that would predict different patterns in the data. For ex-
ample, if the microglia were primarily responding to a
straightforward increase in amyloid burden, then the
prediction would be further upregulation or downregula-
tion of the amyloid-associated transcriptional changes
identified in the KI vs WT comparison. Evidence for this
was not detected in the present study, and this could
imply that certain microglial responses are already max-
imally engaged by one pathology or the other. Alterna-
tively, overall plaque number may not be the primary
driver of these shifts but, instead, levels of soluble Aβ may
be more important. There is also an indication that more
of the microglia are in a DAM state when both patholo-
gies are present, as some DAM transcripts not signifi-
cantly elevated in either the HHcy or amyloid conditions
Fig. 6 Gene transcript levels are significantly altered in the single pathology amyloid or HHcy contexts. Gene transcripts significantly altered
between KI mice on control diet and WT mice on control diet are shown in a, and transcripts significantly altered between WT mice on HHcy
diet and WT mice on control diet are shown in b. Transcript fold changes are log2 normalized in comparison to the WT control diet condition. *p
< .05, ***p < .005, ****p < .0001, multiple t tests, uncorrected
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Fig. 7 Gene transcript levels are significantly altered in the amyloid and HHcy comorbidity condition. Graphs displaying log2 fold change values of all
four groups for the 7 genes differentially expressed between KI control and KI HHcy mice are shown in a. A heatmap summarizing z-score transformed
means of each gene across the 4 groups is displayed in b. *p < .05 versus WT control, †p < .05 versus KI control, multiple t tests, uncorrected
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alone were detectably elevated only in the comorbid con-
dition: Lag3 and Lyz2. Further, many other genes dis-
played that pattern even though statistical significance was
not reached. Interestingly, several homeostatic genes
showed a divergent directionality between the single factor
pathologies and the comorbid condition, indicative of po-
tentially interesting responses unique to the comorbid
context: C1qb, C1qc, Sall1, and Csf1r.
C1qb and C1qc encode parts of complement compo-
nent 1q (C1q), which plays a critical role in synaptic
pruning during development and in pathological condi-
tions such as AD [46]. Although C1qa transcript levels
were not significantly altered in any comparisons, the
overall pattern suggests that there may be enhanced syn-
aptic loss or neuronal dysfunction in the comorbid con-
dition, a possibility worthy of exploration. Sall1 is a
transcription factor that under physiological conditions
inhibits microglial activation and pro-inflammatory re-
sponses [47]. Its upregulation in this context suggests re-
duced microglial reactivity to amyloid, and this may help
to explain the modest effects on the pro-inflammatory
cytokines measured. Csf1r signaling is well-characterized
for its involvement in microglial proliferation and sur-
vival [48]. Recent studies have shown that chronic
pharmacologic suppression of this receptor results in
loss of microglia concomitant with protection against
neurodegenerative changes in the 5xFAD amyloidosis
model [49, 50], and its relative increase might be detri-
mental in this context. Although the specific implication
of transcriptional changes in any particular gene is not
clear, when taken together, these data indicate nonethe-
less that there exists both a potentiation of microglial-
associated stress responses as well as more complex
emergent responses in the comorbid Aβ and HHcy con-
dition. Future studies utilizing more animals of both
sexes, specific cellular isolation techniques, and unbiased
measurement of whole-transcriptome changes will be
useful in clarifying the microglia-specific alterations in
this mixed pathology model. Ultimately, data must also
be compared to samples from relevant patient popula-
tions to assess the external validity of the findings.
Conclusion
Modulation of microglial function represents a promis-
ing area for therapeutic development in Alzheimer’s dis-
ease research. Given the frequent co-occurrence of
multiple pathologies in patients with dementia, the suc-
cess of this approach will likely require a deeper under-
standing of microglial responses in various contexts. The
present study supports such efforts by offering an initial
characterization of both general and unique microglial-
associated changes in response to comorbid amyloidosis
and HHcy. Whether successful treatments will focus on
ameliorating general microglial dysfunction, will be
tailored to specific responses, or both is an open ques-
tion. The present study contributes to the groundwork
necessary for future studies to explore this topic in more
depth.
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